Pacritinib

Manufactured by Merck Group

Pacritinib is a laboratory equipment product manufactured by Merck Group. It is a functional tool used in various research and development applications. The core function of Pacritinib is to facilitate specific experimental procedures, but detailed information about its intended use is not available.

Automatically generated - may contain errors

Lab products found in correlation

Romidepsin, by Focus Biomolecules (2 mentions) Brefeldin a, by MedChemExpress (2 mentions)

3 protocols using pacritinib

Macrocycle Compounds Acquisition Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

All the macrocycle compounds are commercially available. Brefeldin A was purchased from MedChemExpress, romidepsin and troleandomycin from Focus Biomolecules, simeprevir and paritaprevir from Invivochem, and pacritinib from Sigma Aldrich.

Danelius E., Bu G., Wieske H, & Gonen T. (2023). MicroED as a powerful tool for structure determination of macrocyclic drug compounds directly from their powder formulations. bioRxiv.

+ Open protocol

+ Expand

Evaluating Synergistic Effects of Pacritinib and TMZ

Check if the same lab product or an alternative is used in the 5 most similar protocols

BTICs were treated with suboptimal doses of 1 μM pacritinib (CTI Biopharma), 10 μg/mL TMZ (Sigma), or a combination of pacritinib and TMZ. Once spheres had formed in the control conditions, alamarBlue was added and incubated for 6 hours and fluorescence intensity (excitation 540 nm; emission 590 nm) was measured on a SpectraMax M Series Multi-Mode Microplate reader. Percent inhibition was determined by normalizing each well to the control well (0.1% DMSO). In order to determine if there was synergy between pacritinib and TMZ, the bliss independence analysis was used. The following equation was used to determine the bliss expectation: E = (A+B)—(A × B), where A and B are the fractional growth inhibitions of drug A (pacritinib) and B (TMZ) at a given dose. A combination is synergistic when a combination effect above the bliss expectation value is observed [25 ,26 (link)].

Jensen K.V., Cseh O., Aman A., Weiss S, & Luchman H.A. (2017). The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. PLoS ONE, 12(12), e0189670.

+ Open protocol

+ Expand

Macrocycle Compound Acquisition Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

All of the macrocycle compounds
are commercially available. Brefeldin
A was purchased from MedChemExpress, romidepsin and troleandomycin
from Focus Biomolecules, simeprevir and paritaprevir from Invivochem,
and pacritinib from Sigma-Aldrich.

Danelius E., Bu G., Wieske L.H, & Gonen T. (2023). MicroED as a Powerful Tool for Structure Determination of Macrocyclic Drug Compounds Directly from Their Powder Formulations. ACS Chemical Biology, 18(12), 2582-2589.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!